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Inducible Nitric Oxide Synthase Isoform Is a Key
Mediator of Leukostasis and Blood-Retinal Barrier
Breakdown in Diabetic Retinopathy
Ermelindo C. Leal,1,2,3 Ayyakkannu Manivannan,4 Ken-Ichi Hosoya,5 Tetsuya Terasaki,6
Jose´ Cunha-Vaz,1 Anto´nio Francisco Ambro´sio,1,2 and John V. Forrester3
PURPOSE. Nitric oxide (NO) is involved in leukostasis and blood-
retinal barrier (BRB) breakdown in the early stages of diabetic
retinopathy (DR), but it is unclear which NO synthase (NOS)
isoforms are primarily involved. In this study, the authors
aimed to clarify the involvement of constitutive (eNOS, nNOS)
and inducible NOS (iNOS) isoforms and the mechanisms un-
derlying NO-mediated leukostasis and BRB breakdown.
METHODS. Diabetes was induced with streptozotocin for 2
weeks. Mice were treated with a NOS inhibitor, NG-nitro-L-
arginine methyl ester (L-NAME), which shows a preference for
constitutive isoforms over iNOS. Vessel leakage was assessed
with Evans blue. Leukostasis was quantified in flat-mounted
retinas with confocal microscopy, in vivo with a scanning laser
ophthalmoscope, and in vitro in a retinal endothelial cell line.
ICAM-1, occludin, and ZO-1 levels were assessed by Western
blot, flow cytometry, or immunohistochemistry. Nitrotyrosine
content was assessed by immunohistochemistry.
RESULTS. Diabetes increased leukostasis within retinal vessels
and BRB permeability, which were reduced by L-NAME. Similar
effects were observed in diabetic iNOS knockout mice. In
diabetic mouse retinas, ICAM-1 protein levels increased,
whereas the immunoreactivity of tight junction proteins, oc-
cludin and ZO-1 decreased, in correlation with increased pro-
tein levels of all NOS isoforms. Those effects were prevented
by L-NAME and also in diabetic iNOS knockout mice. High
glucose and nitrosative/oxidative stress also increased leuko-
stasis caused by ICAM-1 upregulation.
CONCLUSIONS. These results indicate that the iNOS isoform plays
a predominant role in leukostasis and BRB breakdown. The
mechanism involves ICAM-1 upregulation and tight junction
protein downregulation. (Invest Ophthalmol Vis Sci. 2007;48:
5257–5265) DOI:10.1167/iovs.07-0112
Diabetic retinopathy (DR) is a leading cause of blindness inworking-age adults in the Western world, and chronic
hyperglycemia is known to be the prime triggering factor for
the development of the disease.1,2 Several biochemical abnor-
malities, including increased aldose reductase activity, elevated
nonenzymatic glycation, activation of protein kinase C (PKC),
and oxidative stress have been identified in diabetic retinas and
contribute to endothelial dysfunction.3–6
Oxidative stress induced by diabetes is thought to play a
significant role in DR.7–9 Reactive oxygen and nitrogen species,
including peroxynitrite, a highly reactive oxidant formed by
the rapid combination of nitric oxide (NO) with superoxide
anion, are increased in the retinas of diabetic rats.10–12 This
increase has been correlated with increased leukocyte adhe-
sion to retinal vessels and blood-retinal barrier (BRB) break-
down.13–15 Increased leukostasis in the early stages of DR
occurs through the upregulation of intercellular adhesion mol-
ecule-1 (ICAM-1).16 ICAM-1 upregulation is mediated by NO,
apparently produced by endothelial NO synthase (eNOS).14 It
is possible that the other NOS isoforms, neuronal and inducible
NOS (nNOS and iNOS), are also involved in this process. It is
unclear how the different constitutive and inducible NOS iso-
forms contribute to these events, and the molecular mecha-
nisms of this process are not yet fully understood.
Diabetes-induced BRB breakdown is associated with re-
duced levels of occludin expression, a tight junction pro-
tein, and with its redistribution within the retinal vascular
endothelium.17,18 However, it is unknown whether NO gen-
erated by one NOS isoform or all NOS isoforms is involved in
this effect.
We used a customized scanning laser ophthalmoscope
(SLO) protocol,19 combined with confocal analysis of retinal
whole mount preparations to study the role of NO produced in
vivo, in leukocyte adhesion to retinal vessels, and in BRB
breakdown induced by diabetes in a mouse model of diabetes.
Given that an inflammatory component has been associated
with DR20 and that NO derived from iNOS may play an impor-
tant role in DR, we used iNOS KO mice, which can be consid-
ered the best approach to study the role of iNOS. In addition,
we performed complementary in vitro experiments with a rat
retinal endothelial cell line, TR-iBRB2,21 to further investigate
the mechanism of high glucose–associated leukocyte–endo-
thelial cell adhesion. Our data show that the inducible NOS
isoform was the dominant isoform involved in increased leu-
kocyte adhesion to retinal endothelial vessels and BRB break-
down, in the early stages of DR, by a mechanism involving the
upregulation of ICAM-1 and the downregulation of tight junc-
tion proteins, and mediated by reactive nitrogen species for-
mation and PKC.
METHODS
Animal Models
Inbred male control (C57BL/6J) and iNOS null (C57BL/6-Nos2tm1Lau)
mice, 12 to 20 weeks old, were obtained from the animal facility at the
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Medical School, Aberdeen University (Scotland, UK). The animals were
fed standard laboratory chow and were allowed free access to water in
an air-conditioned room with a 12-hour light/12-hour dark cycle. All
procedures involving animals were performed in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research and in accordance with the regulations of the UK Animal
License Act 1986.
Diabetes was induced in C57BL/6J and in iNOS null mice with a
single intraperitoneal streptozotocin injection (160 mg/kg, in saline).
Two days later, animals with urine glucose levels (reagent strips for
urinalysis; Diastix, Bayer Diagnostics Europe; Dublin, Ireland) higher
than 14 mM were considered diabetic. Blood glucose levels were
measured (BM-test 1–44; Roche, Basel, Switzerland) before the exper-
iments, and animals with glucose levels higher than 16.7 mM were
used.
The following groups of animals were maintained for 2 weeks:
control mice, diabetic untreated mice, control mice treated with the
NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 200 mg/kg
intraperitoneally every other day; Sigma, St. Louis, MO), diabetic mice
treated with L-NAME (D_L-NAME), iNOS null (KO) mice, and diabetic
iNOS null (D_KO) mice.
Leukocyte Labeling
A cell suspension was obtained from the spleen of a normal C57BL/6J
mouse. The cells were resuspended in 20 mL complete medium (RPMI
1640 supplemented with 10% [vol/vol] heat-inactivated fetal calf serum
[FCS], 1% sodium pyruvate, 4 mM L-glutamine, 1 nonessential amino
acid [NEAA]; Gibco BRL, Paisley, UK). To label the cells, 2  107
cells/mL were incubated with 40 g/mL calcein-AM (C-AM; Molecular
Probes Europe, Leiden, The Netherlands) for 30 minutes at 37°C, as
described previously.22 C-AM is nontoxic and has no effect on cell
adhesion.23 The cells were washed, and 1  107 leukocytes in 100 L
RPMI were adoptively transferred into each mouse through the tail
vein.
Leukocyte Adhesion in Whole-Mounted Retinas
and BRB Permeability
Approximately 50 minutes after the infusion of labeled cells, each
animal was injected through the tail vein with 100 L of 2% (wt/vol)
Evans blue (Sigma). Evans blue is a dye that binds to the albumin in the
blood, thus allowing detection of sites of BRB breakdown, where
plasma proteins leak from the vessels. Ten minutes later, the animals
were killed with lethal doses of anesthetic (100 L Euthatal; Merial
Animal Health Ltd., Essex, UK). Their eyes were removed and imme-
diately immersed in 2% (wt/vol) paraformaldehyde (Agar Scientific
Ltd., Cambridge, UK) for 2 hours. Retinal whole flat mounts were
prepared according to the method of Chan-Ling.24 Briefly, the retina
was dissected and spread on clean glass slides and mounted in medium
(Vectashield; Vector Laboratories, Burlingame, CA) vitreous-side up
under coverslips. Retinal flat mounts were analyzed by confocal scan-
ning laser microscopy (LSM 510; Zeiss, Go¨ttingen, Germany) to eval-
uate the number of leukocytes adhering to retinal vessels and the BRB
breakdown sites.
In Vivo Leukocyte Adhesion
The animals were anesthetized with an anesthetic cocktail of 130
g/kg fentanyl (Janssen-Cilag Ltd., Bucks, UK), 10.25 mg/kg midazolam
(Roche), and 3.8 mg/kg acepromazine (ACP; Novartis Animal Health
Ltd., Essex, UK), injected intraperitoneally, producing deep anesthesia
for 45 minutes. Pupils were dilated with one drop of 0.5% (wt/vol)
tropicamide (Chauvin Pharmaceuticals Ltd., Essex, UK), and a hard
contact lens (clear polymethylmethacrylate [PMMA]; refractive index,
1.51; radius of curvature, 1.7 mm; diameter, 3.2 mm; Cantor & Nissel,
Northamptonshire, UK) was placed on the cornea to obtain a clear
view of the eye fundus. Sodium fluorescein (50 L, 0.05% [vol/vol];
Sigma), which has no effect on endothelial cell function, was injected
through the tail vein to outline the vessels, followed by the injection of
1  107 C-AM–labeled cells in 100 L RPMI. In each animal, the areas
adjacent to the optic disc were examined through a custom-built
SLO.19 Real-time retinal images were captured continuously for the first
30 minutes after injection of labeled cells on DVD-R (25 frames/sec) for
image analysis using appropriate software, as previously described.25
Leukocytes were classified as either free-flowing cells or as adherent
cells (sticking cells) if they adhered to the vessels wall for more than 1
second.
Immunolocalization of ICAM-1 and Occludin in
Retinal Vessels
The animals were killed, and the eyes were removed and immersed in
2% (wt/vol) paraformaldehyde for 2 hours. The retinas were dissected,
washed in phosphate-buffered saline (PBS), and permeabilized in 0.3%
Triton X-100 in PBS for 2 hours. The retinas were immersed in blocking
solution (6% of normal mouse serum [NMS]) for 30 minutes and
incubated overnight with fluorescein isothiocyanate (FITC)-conjugated
antibody anti–ICAM-1 (1:100; BD PharMingen, Oxford, UK) or anti-
occludin (1:100; Zymed Laboratories, San Francisco, CA). FITC-conju-
gated hamster IgG and mouse IgG, respectively, were used as isotype
controls. After incubation, the retinas were washed and mounted on
slides for confocal microscopy.
Immunohistochemistry for Nitrotyrosine
in Retina
The animals were killed, and the eyes were frozen in OCT in isopen-
tane at 80°C. Transverse sections with 10 m were obtained on a
cryostat and collected on polylysine-coated slides and then allowed to
air dry for 1 hour. Sections were fixed in acetone for 10 minutes, dried,
and washed with PBS. Then they were immersed with 10% normal
rabbit serum (NRbS) in PBS for 30 minutes and incubated overnight at
room temperature (RT) with a rabbit anti–nitrotyrosine antibody (1:
100; Upstate Biotechnology, Lake Placid, NY) in 3% NMS, 0.3% Triton
X-100. Sections were then washed with PBS, incubated with a FITC-
labeled secondary anti–rabbit antibody (Serotec, Oxford, UK) for 2
hours, washed again, and coverslipped for confocal microscopy.
Confocal Microscopy
All retinal whole mounts and cryosections were examined for Evans
blue and C-AM or for FITC using a confocal scanning laser imaging
system fitted with krypton/argon lasers (LSM 510; Zeiss). With the use
of dual blue and green fluorescence, the Evans blue stain appeared red
and the C-AM or FITC stain appeared green.
Western Blot Analysis
Mouse retinas were washed with cold PBS and lysed in 150 mM NaCl,
50 mM Tris, 5 mM EGTA, 1% Triton X-100, 0.5% deoxycholate, and
0.1% SDS supplemented with complete mini-protease inhibitor cock-
tail tablets (Roche). Protein concentration was determined by the
bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology,
Rockford, IL), and 30 g protein (when blotting for occludin and
ZO-1), 50 g protein (when blotting for eNOS, nNOS, and ICAM-1) or
100 g protein (when blotting for iNOS) from each sample was used
for Western blot analysis, after 6 concentrated sample buffer (0.5 M
Tris, 30% glycerol, 10% SDS, 0.6 M dithiothreitol [DTT], 0.012% bro-
mophenol blue) was added and the samples were heated for 5 minutes
at 95°C. Proteins were separated by electrophoresis on 9% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred electrophoretically to polyvinylidene difluoride (PVDF)
membranes. The membranes were blocked for 1 hour at RT, in Tris-
buffered saline (137 mM NaCl, 20 Tris-HCl, pH 7.6) containing 0.1%
Tween-20 (TBS-T) and 5% low-fat milk. Incubation with the primary
antibodies rabbit anti–ZO-1 (1:2000), rabbit anti–occludin (1:250;
Zymed Laboratories), mouse anti–eNOS (1:1000), mouse anti–nNOS
(1:2000), rabbit anti–iNOS (1:2500; BD Transduction Laboratories, San
Jose, CA), and goat anti–ICAM-1 (1:200; Santa Cruz Biotechnology) was
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performed overnight at 4°C. After washing for 1 hour in TBS-T with
0.5% low-fat milk, the membranes were incubated for 1 hour at RT
with alkaline phosphatase-linked secondary antibodies (goat anti–rab-
bit IgG, goat anti–mouse IgG, or rat anti–goat IgG; 1:20,000 in TBS-T
with 1% low-fat milk; Amersham, Buckinghamshire, UK). Protein im-
munoreactive bands were visualized using enhanced chemifluores-
cence (ECF) substrate (ECF Western Blotting Reagent Pack; Amer-
sham), and fluorescence was detected on an imaging system (Storm
860 Gel and Blot Imaging System; Molecular Dynamics, Amersham).
Endothelial Cell Culture
Rat retinal endothelial cells (TR-iBRB2 cell line)21 were cultured in
low-glucose DMEM (Gibco BRL, Paisley, UK) containing 10% heat-
inactivated fetal bovine serum (FBS), 17.8 mM sodium bicarbonate, 0.1
mg/mL streptomycin, and 100 IU/mL penicillin. Cells were maintained
at 33°C in a humidified atmosphere of 5% CO2/air. Cells were incu-
bated with 24.5 mM glucose (final concentration, 30 mM) or with 24.5
mM mannitol (with 5.5 mM glucose; osmotic control) for 24 hours or
4 days. Endothelial cells were also incubated with 100 M H2O2 or 250
M NOC-18 (NO donor) for 24 hours and were treated with 50 M
L-NAME or with 100 nM LY379196 (PKC inhibitor; a kind gift from Eli
Lilly), as indicated in the figure legends.
Leukocyte Adhesion In Vitro
With the use of a simple cell–cell adhesion microplate assay, the
binding of fluorescently labeled rat (Dark Agouti) leukocytes in sus-
pension to a monolayer of retinal endothelial cells was studied, as
previously described.26 Briefly, endothelial cells were plated in a 96-
well microtiter plate at a concentration of 0.25  106 cells/mL and
were allowed to grow to confluence overnight. Leukocytes were
harvested and labeled with C-AM, as previously described. The suspen-
sion of leukocytes was added to the monolayer of endothelial cells (2
105 leukocytes/well) for 90 minutes at 37°C. After incubation, nonad-
herent cells were removed by gentle washing with RPMI. The emitted
fluorescence (arbitrary units) was measured in a fluorescence plate
reader (Fluorite 1000; Dynex Technologies, West Sussex, UK) at an
excitation wavelength of 490 nm and an emission wavelength of 530
nm. Endothelial cells were incubated with the antibody against ICAM-1
(40 g/mL) 2 hours before the adhesion assay.
Flow Cytometry Analysis of ICAM-1 Expression in
Endothelial Cells
Endothelial cells (TR-iBRB2 cell line) were harvested after gentle tryp-
sin (1; Sigma) digestion. A total of 1  106 cells were incubated with
a specific antibody against rat ICAM-1 (1:100; BD PharMingen) in 1%
(vol/vol) FCS and 6% (vol/vol) NRbS in PBS, at 4°C for 30 minutes. After
incubation, the cells were washed with 1% (vol/vol) FCS in PBS and
stained with an anti–rat antibody (rabbit IgG; 1:100; Sigma) for 30
minutes at 4°C. Flow cytometry was performed (FACSCalibur; BD
Biosciences, San Jose, CA), and the results were analyzed (CellQuest
software; BD Biosciences).
Statistical Analysis
Data are expressed as mean  SD. Statistical significance was deter-
mined by analysis of variance (ANOVA), followed by Dunnett or Bon-
ferroni post hoc test, as indicated in the figure legends.
RESULTS
Nitric Oxide Mediates Diabetes-Induced Increase
in Leukocyte Adhesion to Retinal Vessels and
BRB Breakdown
The relative contribution of NO, generated from constitutive
(eNOS and nNOS) or inducible (iNOS) sources, to the adhesion
of leukocytes to retinal vessels induced by diabetes was eval-
uated in normal (C57BL/6J) and iNOS knockout (C57BL/6-
Nos2tm1Lau) mice. Leukocyte adhesion to retinal vessels was
assessed in whole-mounted retinas (Figs. 1A, 1B) and in vivo
(Fig. 1C). Because we were interested in evaluating the contri-
bution of the retinal vessels and surrounding environment to
leukostasis, only normal leukocytes were transferred into mice.
The number of leukocytes in whole-mounted retinas was sig-
nificantly increased in diabetic retinas (46  9 leukocytes)
compared with the retinas isolated from normal mice (26  5
leukocytes; Figs. 1A, 1B, 1D). Treatment of diabetic mice with
L-NAME, which inhibits all three NOS isoforms but shows a
preference for constitutive isoforms over iNOS,27 significantly
reduced the number of leukocytes (32  4 leukocytes) com-
pared with diabetic animals (Figs. 1A, 1B, 1D). Treatment of
control animals with L-NAME did not cause any significant
change. Similar results were obtained in in vivo experiments.
Diabetes induced an increase in the number of adherent leu-
kocytes (73  17 in the retinal vessels located near the optic
disc; Figs. 1C, 1E) compared with control retinas (31  9
adherent leukocytes). L-NAME treatment reduced the number
of adherent leukocytes in diabetic retinas to 37  9 (Fig. 1E),
and no effect was observed with L-NAME treatment in normal
mouse retinas. In the retinas of diabetic iNOS KO mice, signif-
icantly fewer leukocytes were observed in whole-mounted
retinas and SLO experiments (31  4 and 47  10 leukocytes,
respectively) than in retinas of diabetic mice (46  9 and 73 
17 leukocytes, respectively; Figs. 1D, 1E).
The breakdown of the BRB induced by diabetes was evalu-
ated by analyzing the leakage of Evans blue from retinal vessels
(Fig. 1A). Retinas of control mice revealed normal retinal vessel
architecture with no detectable leakage. After 2 weeks of
diabetes, BRB breakdown was evidenced by extensive Evans
blue leakage from retinal vessels into the tissue parenchyma. In
diabetic mice treated with L-NAME and in diabetic iNOS KO
mice, a decrease in dye leakage was clearly observed (Fig. 1A).
Nitric Oxide Mediates Diabetes-Induced Increase
in ICAM-1 Retinal Expression
It has been shown that the adhesion of leukocytes to retinal
vessels is mediated, at least in part, by ICAM-1, which is
upregulated in diabetic retinal endothelial cells. Therefore,
we sought to determine whether NO-mediated leukocyte–
endothelial cell adhesion in diabetic mice was caused by
ICAM-1 upregulation. Protein expression levels of ICAM-1 in
diabetic retinas increased to 159.7%  38.3% of the control,
and this effect was inhibited by treatment with L-NAME
(109.5%  14.6% of the control; Fig. 2A). In diabetic iNOS
KO mice, ICAM-1 expression levels were similar to those
found in control retinas (108.4%  29.0% of control; Fig.
2B). Protein expression levels of ICAM-1 were not altered in
the retinas of nondiabetic animals treated with L-NAME or in
iNOS KO mice.
In addition, the immunoreactivity of ICAM-1 increased in
retinal vessels of diabetic animals, and this effect was inhibited
by L-NAME treatment. The immunoreactivity of ICAM-1 in the
retinas of nondiabetic and diabetic iNOS KO mice was similar
to the immunoreactivity observed in the retinas of control mice
(Fig. 2C).
Nitric Oxide Mediates Diabetes-Induced
Downregulation of the Tight Junction Proteins
Occludin and ZO-1
To determine whether increased retinal vessel leakage, ob-
served in diabetic mice, was caused by alterations in the con-
tent of tight junction proteins, the expression of occludin and
ZO-1, two important tight junction proteins, was analyzed by
Western blotting and immunocytochemistry in retinal homog-
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enates and retina whole mounts, respectively. Occludin and
ZO-1 protein levels decreased to 81.1%  9.3% and 74.0%
10.0% of the control, respectively, in diabetic retinas (Figs.
3A, 3B). Treatment of diabetic mice with L-NAME prevented
the decrease in occludin and ZO-1 protein levels induced by
diabetes, indicating that NO mediates the downregulation of
tight junction proteins and could thus explain in part the
breakdown in BRB function. Similarly, the reduction in the
protein levels of occludin and ZO-1 induced by diabetes was
prevented in diabetic iNOS KO mice (Figs. 3C, 3D).
In control mice, occludin was strongly expressed in endo-
thelial cell membranes of retinal vessels, whereas it was mark-
edly reduced and sometimes absent or more diffusely distrib-
uted in diabetic mice. This dysregulation of occludin
expression was prevented by treatment with L-NAME and in
iNOS KO diabetic mice (Fig. 3E). Because ZO-1 is also ex-
pressed in the cytosol of neural cells, it was difficult to evaluate
changes of this protein in retinal vessels (not shown).
Nitric Oxide Mediates Diabetes-Induced
Upregulation of Nitric Oxide Synthase Isoforms
Feedback upregulation of eNOS is mediated by NO itself.14
Therefore, we examined protein expression levels of the three
NOS isoforms (eNOS, nNOS, iNOS) in diabetic mice by quan-
titative Western blotting of mouse retinal homogenates. Diabe-
tes increased the protein levels of eNOS (151.3%  39.4% of
the control), nNOS (143.8%  16.2% of the control), and iNOS
(174.6%  67.5% of the control; Figs. 4A–C). Treatment with
L-NAME inhibited the increase in protein levels of NOS iso-
forms, particularly those of eNOS (106.3%  36.0% of the
control; Fig. 4A) and iNOS (113.7% 46.5% of the control; Fig.
4C), but did not cause a significant reduction of nNOS protein
levels (124.7%  18.8% of the control; Fig. 4B). These results
suggest that NO itself upregulates the expression of NOS iso-
forms in a positive feedback mechanism. Treatment of nondi-
abetic mice with L-NAME did not alter the expression levels of
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FIGURE 1. Effect of diabetes on retinal leukostasis and BRB breakdown: involvement of NO. Leukocytes stained with C-AM, isolated from the
spleens of control mice, were injected, through the tail veins of mice in different groups: control (C), treated with L-NAME (L-NAME), diabetic (D),
diabetic treated with L-NAME (D_L-NAME), iNOS KO (KO), and diabetic iNOS KO (D_KO). (A) Representative images of accumulating leukocytes
and vessel leakage in whole-mounted retinas. Evans blue (red) injected through the tail vein 10 minutes before animal kill, outlines retinal vessels,
allowing the detection of BRB breakdown. Small arrows: trapped leukocytes (green). Large arrows: vessel leakage. Scale bar, 200 m. (B)
Representative images of accumulating leukocytes at higher magnification. Scale bar, 100 m. (C) Representative SLO image of a diabetic retina
with adherent leukocytes. (D) Quantification of leukocytes trapped in whole-mounted retinas. Data represent the number of leukocytes in the
entire retina in each condition tested, as indicated below the bars. (E) Quantification of adherent leukocytes in vivo using an SLO. Data are
presented as mean  SD of at least six mice. *P  0.05 and ***P  0.001 compared with control mice; Dunnett posttest. ###P  0.001 compared
with diabetic mice; Bonferroni posttest.
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the three NOS isoforms. The protein levels of NOS isoforms in
the retinas of iNOS KO mice, eNOS and nNOS, were not
significantly different (116.5%  36.4% and 130.2%  13.4% of
the control, respectively) from the eNOS and nNOS protein
levels detected in the retinas of control mice (Figs. 4D, 4E). In
addition, the induction of diabetes in iNOS KO mice did not
significantly increase the protein levels of eNOS and nNOS,
though they were significantly different from those of nondia-
betic controls (148.9%  23.5% and 150.5%  6.5% of the
control, respectively).
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FIGURE 3. Effect of diabetes on the expression of occludin and ZO-1 in the mouse retina: involvement of NO. Occludin (A, C) and ZO-1 (B, D)
expression were analyzed by Western blotting in retinal homogenates obtained from control and diabetic mice, treated or not treated with L-NAME,
and in nondiabetic and diabetic iNOS KO mice, as indicated below bars. Western blots are representative of each group of mice, composed of at
least six animals. (E) Representative images of occludin immunostaining in mouse retinas, obtained from different groups of mice, as indicated in
the images. Scale bar, 50 m. Results are presented as percentage of control and represent the mean  SD. *P  0.05 and **P  0.01 compared
with control mice; Dunnett posttest.
IOVS, November 2007, Vol. 48, No. 11 Inducible NOS in Diabetic Retinopathy 5261
Diabetes Increases Protein Nitration in the Retina
Peroxynitrite (ONOO) is a short-lived molecule that results from
the reaction of NO with superoxide and can attack a wide range
of biological molecules. Peroxynitrite produces stable nitration of
protein tyrosine residues, impairing protein function.28 Because
the formation of nitrotyrosine is correlated with NO production,
determining the nitrotyrosine content is usually considered an
indirect measure of NO production. Nitrotyrosine content was
assessed by immunohistochemistry in mouse retinas (Fig. 5).
Nitrotyrosine immunostaining increased in diabetic retinas,
namely in ganglion cell layer (GCL) and outer plexiform layer
(OPL), and treatment with L-NAME prevented the increase in
nitrotyrosine formation. The induction of diabetes in iNOS KO
mice did not increase nitrotyrosine formation.
High Glucose Level and Oxidative/Nitrosative
Stress Increase In Vitro Leukocyte Adhesion to
Retinal Endothelial Cells: Involvement of NO
and PKC
The adhesion of leukocytes to retinal endothelial cells was also
evaluated using an in vitro assay. The leukocytes used in these
experiments were obtained from the spleens of normal rats.
High glucose (30 mM, 4 days) increased leukocyte adhesion to
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FIGURE 4. Effect of diabetes on the
expression of NOS isoforms in
mouse retina: involvement of NO.
Expression of eNOS (A, D), nNOS (B,
E), and iNOS (C) were analyzed by
Western blotting in retinal homoge-
nates obtained from control and dia-
betic mice, treated or not treated
with L-NAME, and in nondiabetic or
diabetic iNOS KO mice, as indicated
below bars. Western blots are repre-
sentative of each group of mice,
composed of at least six animals. Re-
sults are presented as percentage of
control and represent the mean 
SD. *P  0.05 and **P  0.01 com-
pared with control mice; Dunnett
posttest.
Control Diabetic Diabetic L-NAME Diabetic iNOS KOiNOS KO
FIGURE 5. Effect of diabetes on nitrotyrosine formation in mouse retina: involvement of NO. Representative images of nitrotyrosine immuno-
staining in mouse retinas, obtained from different groups of mice, as indicated. Scale bar, 100 m.
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endothelial cells (Fig. 6A; 119.5%  10.1% of the control), and
this effect was prevented by L-NAME. The incubation of endo-
thelial cells with an inhibitor of PKC (LY379196, 100 nM) or
with an antibody against ICAM-1, which was added to block
ICAM-1 2 hours before the leukocyte adhesion assay, also
prevented the increase in leukocyte adhesion induced by high
glucose. L-NAME, LY379196, or the antibody against ICAM-1
did not alter leukocyte adhesion to control endothelial cells
(not shown).
Exposure of retinal endothelial cells to a NO donor, NOC-
18, or H2O2 for 24 hours also increased the adhesion of leu-
kocytes to endothelial cells (141.0%  9.7% and 121.8% 
12.5% of the control, respectively; Figs. 6B, 6C). These effects
were prevented by LY379196 or by the antibody against
ICAM-1 (Figs. 6B, 6C), indicating a general effect of free radi-
cals on ICAM-1 upregulation.
The effect of high glucose, NOC-18, or H2O2 on the expres-
sion of ICAM-1 in retinal endothelial cell membranes was ana-
lyzed by flow cytometry. High glucose (24-hour or 4-day expo-
sure) significantly increased ICAM-1 levels in endothelial cells
(122.0%  12.4% and 121.0%  3.4% of the control, respec-
tively; Fig. 7A). Similar results were obtained when endo-
thelial cells were exposed to NOC-18 or H2O2 for 12 or 24
hours (Fig. 7B).
DISCUSSION
Diabetes increases leukocyte adhesion to retinal vessels and
induces the breakdown of BRB,29,30 and it has been shown that
NO can mediate these events.13,14 NO is synthesized by con-
stitutive and inducible NOS isoforms; hence, it is important to
understand the relevance of the different NOS isoforms in this
process and the mechanisms involved. Previous studies have
suggested that constitutive NOS mediates those early events in
DR13,14; however, given that an inflammatory component has
been shown to occur in early DR,10,31,32 the iNOS isoform
could also be an important potential contributor to NO gener-
ation at this interface. iNOS mediates retinal apoptosis in late
DR events such as ischemic proliferative retinopathy,33 and it
modulates progenitor and resident endothelial cell behavior in
galactosemia.34 Given that iNOS is involved in inflammation, a
selective deletion of iNOS, leading to a decrease in leukostasis
and in BRB breakdown in diabetes, would support its involve-
ment in these early pathogenic processes. Others have shown
that aminoguanidine, used as an iNOS inhibitor, can prevent a
diabetes-mediated increase in nitrosative stress, iNOS expres-
sion, and NOS activity in the retina.11,35,36 However, amino-
guanidine is not the best tool to evaluate the role of iNOS
because it is only effective in vivo at high doses.27 In addition,
it is not specific for iNOS because it also inhibits the formation
of advanced glycosylation products (AGEs) thought to play a
major role in the pathogenesis of diabetic complications.37,38
Thus, the use of iNOS KO mice can be considered an excellent
tool to study the role of iNOS in DR.
We have found that NO derived from iNOS is strongly
involved in the induction of early vascular changes, suggesting
that iNOS has a key role in early DR. Constitutive NOS isoforms
may have similar effects, especially when tested in vitro, but
Co
nt
ro
l
Gl
uc
os
e
G_
L-
NA
ME
G_
PK
Ci
G_
IC
AM
-1
0
25
50
75
100
125
150
175
**
Le
uc
oc
yt
e
A
dh
es
io
n
(%
 o
f c
on
tr
ol
)
Co
nt
ro
l
NO
C1
8
NO
C1
8_
PK
Ci
NO
C1
8_
IC
AM
-1
0
25
50
75
100
125
150
175
**
Le
uk
oc
yt
e
A
dh
es
io
n
(%
 o
f c
on
tr
ol
)
CBA
Co
nt
ro
l
H2
O2
H2
O2
_P
KC
i
H2
O2
_I
CA
M
-1
0
25
50
75
100
125
150
175
**
L
eu
ko
cy
te
A
dh
es
io
n
(%
 o
f c
on
tr
ol
)
FIGURE 6. Quantification of in vitro leukocyte adhesion to endothelial cells. Leukocytes isolated from the spleens of normal rats were stained with
C-AM and then incubated with retinal endothelial cells for 90 minutes. Leukocyte adhesion was quantified by a fluorometric assay. (A) Endothelial
cells exposed to high glucose (30 mM, G), for 4 days, were treated with L-NAME (50 M), a PKC inhibitor (LY379196, 100 nM), or with an antibody
against ICAM-1 (40 g/mL). (B, C) Endothelial cells exposed to NOC-18 (250 M) or H2O2 (100 M) for 24 hours were treated with a PKC inhibitor
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four independent experiments, made in triplicate. **P  0.01, compared with control; Dunnett posttest.
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FIGURE 7. Effect of high glucose,
NOC-18, or H2O2 on ICAM-1 expres-
sion in retinal endothelial cells.
ICAM-1 expression was measured by
flow cytometry. (A) Endothelial cells
were exposed to 30 mM glucose for
24 hours or 4 days. (B) Endothelial
cells were exposed to NOC-18 (250
M) or H2O2 (100 M) for 12 or 24
hours. Data are presented as percent-
age of control and represent the
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dent experiments. *P  0.05 and
**P  0.01 compared with control;
Dunnett posttest.
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they have no significant additional or synergistic effects in vivo
because in the presence of constitutive NOS, but deleted iNOS,
diabetes-induced leukostasis and BRB breakdown is signifi-
cantly inhibited or even prevented. Indeed, despite the fact
that constitutive NOS is upregulated in diabetic iNOS KO mice,
diabetic-induced leukostasis and BRB breakdown is largely pre-
vented. However, the involvement of constitutive NOS cannot
be completely ruled out because all NOS isoforms were up-
regulated in the retinas of diabetic mice.
Nitric oxide, in the presence of superoxide, rapidly forms
peroxynitrite, a strong oxidant that can be generated in several
cell types (Mu¨ller cells, astrocytes, microglial cells, neurons,
endothelial cells). Peroxynitrite reacts with proteins, leading to
the addition of a nitro group to tyrosine residues to form
nitrotyrosine. In diabetic rat retinas, nitrotyrosine formation
was detected in the retinal vasculature and where blood ves-
sels are found (GCL, IPL, OPL).11,39 We also detected nitroty-
rosine formation in GCL and OPL. Sites of nitrotyrosine depo-
sition are determined by superoxide formation because
superoxide cannot cross cell membranes.40 In contrast, NO
can freely cross cell membranes and can exert action in other
cells. Thus, peroxynitrite may be generated in nearly all cell
types in the retina during diabetes. The blood-retinal barrier is
influenced by Mu¨ller cells and astrocytes18,41 but may be af-
fected indirectly by microglial cells and neurons through re-
leased factors.42,43 Therefore, the observed effects in retinal
vasculature might be attributed not only to alterations in en-
dothelial cells but also to the dysfunction of other cell types.
The mechanism by which NO mediates the effects of dia-
betes on the retinal vasculature was also studied. Our data
revealed that the major effect of NO production is to upregu-
late ICAM-1 in endothelial cells, which thus promotes leuko-
cyte adhesion. Conversely, NO promoted the downregulation
of the tight junction proteins occludin and ZO-1, leading to the
breakdown of BRB. Other studies, in pulmonary epithelium
and in kidney cells, showed that NO mediates the downregu-
lation of tight junction protein expression and the irregular
tight junction staining.44,45 Our in vitro data also suggested that
NO is responsible for the high glucose-induced ICAM-1 in-
crease and its downstream effect on leukocyte adhesion. In-
deed this may be a general effect of free radicals, in which PKC
is also involved.
Based on our findings we hypothesize that the mechanism
of damage to retinal vessels in diabetes is an initial glucose-
mediated injury to the endothelium, leading to an increase in
NO production by the upregulation of constitutive and induc-
ible NOS expression, which then induces an upregulation in
ICAM-1 expression and an increase in leukocyte adhesion. Our
results indicate that iNOS is mainly involved. Therefore, the
process can be amplified by NO released through iNOS, which
produces high amounts of NO, further compounding the dam-
age to the endothelium. This leads progressively to greater
areas of small vessel and capillary closure, which over time
produce increasingly large areas of retinal ischemia, despite
attempts by the retina to induce new capillary formation and
reperfusion.
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